Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca will keep UK investment freeze if no Brexit clarity

share with twitter share with LinkedIn share with facebook
10/15/2018 | 12:46pm EDT
A sign is seen at an AstraZeneca site in Macclesfield

PARIS (Reuters) - AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday.

The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland.

"If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.

"A Brexit agreement will need to ensure that Britain does not become an isolated island in the middle of the Atlantic Ocean," he added.

A spokesman for AstraZeneca said Johansson was referring to a freeze on investments in manufacturing announced in 2017.

"There has been no change to our investment plans in the UK," the spokesman said.

AstraZenca has already spent 40 million pounds ($53 million) stockpiling medicines in Britain and continental Europe to prevent supply disruptions if the two sides fail to reach a withdrawal agreement.

Some pharmaceutical companies including AstraZeneca have warned of medicine shortages in the event of a 'no deal' Brexit.

More than 2,600 drugs have some part of their manufacturing carried out in Britain. Britain exports some 45 million medical packs to EU countries each month, industry figures show, while 37 million flow to Britain from the EU.

France's largest drugmaker Sanofi said in August it would increase medicine stockpiles in Britain, echoing moves made by GlaxoSmithKline, Roche and Novartis.

"In business, uncertainty often forces you to make decisions. But what is frustrating is to have to do so when the existing system works very well," Johansson said. "This is costing us money and brings us no benefit."

($1 = 0.7602 pounds)

(Reporting by Inti Landauro; Editing by Richard Lough and Mark Potter)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.26% 8056 Delayed Quote.6.18%
CHANGE INC. 0.24% 8230 End-of-day quote.466.02%
GLAXOSMITHKLINE PLC 1.20% 1361 Delayed Quote.-24.41%
NOVARTIS AG -2.86% 74.15 Delayed Quote.-16.94%
ROCHE HOLDING AG 0.35% 300.75 Delayed Quote.-4.55%
SANOFI -2.20% 81 Real-time Quote.-7.59%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
12:36pEU warns not enough COVID vaccines for all in Europe until 2022
12:36pUK starts real-time review of Moderna's COVID-19 vaccine candidate
11:53aPfizer Says Covid-19 Vaccine Late-Stage Trial Almost Fully Enrolled -- 2nd Up..
11:24aMerck says early data from COVID-19 vaccines expected this year
10:12aNovavax delays U.S. trial of COVID-19 vaccine to November
09:58aMODERNA : UK starts real-time review of Moderna's COVID-19 vaccine candidate
08:14aPandemic Dents Third-Quarter Sales for Pfizer -- Update
06:57aASTRAZENECA : WRAPUP 6-Europe enacts new curbs as COVID surges in absence of vac..
05:34aEuropean shares sink to one-month lows as COVID-19 cases surge
04:25aS.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate
More news
Financials (USD)
Sales 2020 26 684 M - -
Net income 2020 3 050 M - -
Net Debt 2020 13 182 M - -
P/E ratio 2020 48,7x
Yield 2020 2,68%
Capitalization 138 B 139 B -
EV / Sales 2020 5,66x
EV / Sales 2021 4,94x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,34 $
Last Close Price 105,12 $
Spread / Highest target 47,9%
Spread / Average Target 12,6%
Spread / Lowest Target -37,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381